CIS
CYTK icon

Capital International Sarl’s Cytokinetics CYTK Stock Holding History

Capital International Sarl’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$502K Hold
5,890
– – 0.01% 265
2026
Q1 		$388K Buy
+5,890
New +$374K 0.01% 271

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Sarl's CYTK Position: Q2 2026 in Review

Capital International Sarl held its Cytokinetics (CYTK) position steady in Q2 2026 at 5,890 shares worth $502K. The position accounts for 0.01% of the portfolio, ranked #265.

Capital International Sarl first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Capital International Sarl held 5,890 shares of Cytokinetics worth $502K as of Q2 2026.
  • Capital International Sarl left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up 0.01% of Capital International Sarl's portfolio in Q2 2026, its #265 holding.
  • Capital International Sarl first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Capital International Sarl's 13F filing for Q2 2026, filed 12 Aug 2026.